Figure 4From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer Frequency of grade I-IV neutropenia-related events in patients at base II on day 14 of three courses of FAC and AC chemotherapies. Back to article page